Ocugen reported better-than-expected third-quarter results and provided a positive business update: * Revenue of $1.95 million surpassed consensus estimates of $1.08 million. * Adjusted loss of $0.01 per share was significantly better than the expected loss of $0.06 per share. * The company also highlighted a new regional licensing agreement for OCU400 in the Middle East and North Africa (MENA) and continued progress across its gene-therapy programs, including OCU410 and OCU410ST.